What is the role of anticoagulant therapy in the treatment of Budd-Chiari syndrome?

Updated: Oct 10, 2018
  • Author: Praveen K Roy, MD, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

Anticoagulation is needed in some patients, especially those with underlying hematologic disorders as the cause of Budd-Chiari syndrome.

Prothrombin time and activated partial thromboplastin time should be monitored once anticoagulation is started and should be maintained within the therapeutic range.

The European Association for the Study of the Liver (EASL) indicates that in the setting of adequately treated complications of portal hypertension, anticoagulant therapy is not contraindicated. [48]  A brief interruption in anticoagulation therapy may be considered in patients undergoing an invasive procedure, including paracentesis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!